A Phase 1/2 Study of EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With Metastatic Castration-Resistant Prostate Cancer
Latest Information Update: 14 May 2024
At a glance
- Drugs Enzalutamide (Primary) ; Masofaniten (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors ESSA Pharma
- 14 May 2024 According to an ESSA Pharma media release, expansion to european clinical sites is in progress with an additional 15 clinical sites planned to be activated by 3Q24.
- 14 May 2024 According to an ESSA Pharma media release, the company projecting completion of enrollment in 1Q25, with preliminary data expected in mid-2025.
- 13 Feb 2024 According to an ESSA Pharma media release, expansion to European sites is in progress.